StockData
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS) stock

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)

Close on Nov 17, 2026Market cap $287.64MP/E –Yield –

Emergent BioSolutions operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Emergent BioSolutions's operating cash flow for the twelve months ending Sep 30, 2026 was $200.10M, up 1439.2% year over year. For fiscal 2025 it was $170.60M, up 190.6% from the year before. Over ten years it grew 14.9% a year on average. The highest annual figure on record is $536.90M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$170.60M+190.6%
FY2024Dec 31, 2024$58.70M–
FY2023Dec 31, 2023-$206.30M–
FY2022Dec 31, 2022-$34.10M-110.6%
FY2021Dec 31, 2021$320.20M-40.4%
FY2020Dec 31, 2020$536.90M+185.6%
FY2019Dec 31, 2019$188.00M+349.8%
FY2018Dec 31, 2018$41.80M-79.9%
FY2017Dec 31, 2017$208.10M+281.1%
FY2016Dec 31, 2016$54.60M+28.4%
FY2015Dec 31, 2015$42.52M-62.1%
FY2014Dec 31, 2014$112.32M+15.8%
FY2013Dec 31, 2013$96.97M+144.6%
FY2012Dec 31, 2012$39.64M+225.3%
FY2011Dec 31, 2011$12.19M-87.6%
FY2010Dec 31, 2010$98.02M+228.2%
FY2009Dec 31, 2009$29.87M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$100.10M–
Q2 FY2026Jun 30, 2026$56.10M-47.3%
Q1 FY2026Mar 31, 2026-$33.80M–
Q4 FY2025Dec 31, 2025$77.70M–
Q3 FY2025Sep 30, 2025-$2.30M-101.5%
Q2 FY2025Jun 30, 2025$106.40M+124.0%
Q1 FY2025Mar 31, 2025-$11.20M–
Q4 FY2024Dec 31, 2024-$79.90M-348.9%
Q3 FY2024Sep 30, 2024$153.70M+156.2%
Q2 FY2024Jun 30, 2024$47.50M–
Q1 FY2024Mar 31, 2024-$62.60M–
Q4 FY2023Dec 31, 2023$32.10M-65.4%
Q3 FY2023Sep 30, 2023$60.00M–
Q2 FY2023Jun 30, 2023-$114.40M–
Q1 FY2023Mar 31, 2023-$184.00M–
Q4 FY2022Dec 31, 2022$92.80M-71.7%
Q3 FY2022Sep 30, 2022-$74.00M-543.1%
Q2 FY2022Jun 30, 2022-$15.60M–
Q1 FY2022Mar 31, 2022-$37.30M-831.4%
Q4 FY2021Dec 31, 2021$328.10M+33.4%
Q3 FY2021Sep 30, 2021$16.70M-84.1%
Q2 FY2021Jun 30, 2021-$29.70M-123.2%
Q1 FY2021Mar 31, 2021$5.10M-91.2%
Q4 FY2020Dec 31, 2020$246.00M+101.5%
Q3 FY2020Sep 30, 2020$105.20M–
Q2 FY2020Jun 30, 2020$127.90M–
Q1 FY2020Mar 31, 2020$57.80M-44.8%
Q4 FY2019Dec 31, 2019$122.10M–
Q3 FY2019Sep 30, 2019-$3.10M-101.8%
Q2 FY2019Jun 30, 2019-$35.80M-203.5%
Q1 FY2019Mar 31, 2019$104.80M–
Q4 FY2018Dec 31, 2018-$165.80M-314.0%
Q3 FY2018Sep 30, 2018$174.00M+398.0%
Q2 FY2018Jun 30, 2018$34.60M-35.9%
Q1 FY2018Mar 31, 2018-$1.00M-102.4%
Q4 FY2017Dec 31, 2017$77.49M–
Q3 FY2017Sep 30, 2017$34.94M–
Q2 FY2017Jun 30, 2017$54.00M–
Q1 FY2017Mar 31, 2017$41.67M–
Q4 FY2016Dec 31, 2016-$12.65M–

More Emergent BioSolutions figures

See a number that looks wrong?